# Encompass Health Corp (EHC)

Informational only - not investment advice.

CIK: 0000785161
SIC: 8060 Services-Hospitals
SIC breadcrumb: [Services](/division/I/) > [SIC Major Group 80](/major-group/80/) > [SIC 8060 Services-Hospitals](/industry/8060/)
Latest 10-K filed: 2026-02-26
SEC page: https://www.sec.gov/edgar/browse/?CIK=785161
Filing source: https://www.sec.gov/Archives/edgar/data/785161/000078516126000081/ehc-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-26 · accession 0000785161-26-000081 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000785161.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 5,935,200,000 USD | 2025 | verified |
| Net income | 566,200,000 USD | 2025 | verified |
| Assets | 7,089,700,000 USD | 2025 | verified |
| Free cash flow | 439,200,000 USD | 2025 | computed |
| Net margin | 9.54% | 2025 | computed |
| Revenue YoY | +10.46% | 2025 | computed |
| ROE | 23.22% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | EHC | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 9.5% | 3.2% | 91 | 56 |
| Revenue growth | 10.5% | 11.8% | 45 | 57 |
| FCF margin | 7.4% | 5.4% | 60 | 48 |
| ROE | 23.2% | 7.9% | 88 | 53 |
| ROA | 8.0% | 2.8% | 88 | 58 |
| Liabilities / equity | 1.56 | 1.13 | 57 | 54 |
| Current ratio | 1.08 | 1.63 | 25 | 58 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 80 SIC Major Group 80, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 5935200000 | USD | 2025 | 2026-02-26 |
| Net income | 566200000 | USD | 2025 | 2026-02-26 |
| Assets | 7089700000 | USD | 2025 | 2026-02-26 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-26. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000785161.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 3,642,600,000 | 3,913,900,000 | 4,277,300,000 | 4,605,000,000 | 3,566,300,000 | 4,014,900,000 | 4,348,600,000 | 4,801,200,000 | 5,373,200,000 | 5,935,200,000 |
| Net income | 247,600,000 | 271,100,000 | 292,300,000 | 358,700,000 | 284,200,000 | 412,200,000 | 271,000,000 | 352,000,000 | 455,700,000 | 566,200,000 |
| Diluted EPS | 2.59 | 2.84 | 2.93 | 3.61 | 2.85 | 4.11 | 2.70 | 3.47 | 4.46 | 5.54 |
| Operating cash flow |  |  |  |  |  | 715,800,000 | 705,800,000 | 850,800,000 | 1,002,800,000 | 1,175,600,000 |
| Capital expenditures |  |  |  |  |  | 545,700,000 | 584,100,000 | 583,100,000 | 642,500,000 | 736,400,000 |
| Dividends paid | 83,800,000 | 91,500,000 | 100,800,000 | 108,700,000 | 111,800,000 | 112,200,000 | 99,000,000 | 60,400,000 | 62,800,000 | 71,100,000 |
| Share buybacks | 65,600,000 | 38,100,000 | 0.00 | 45,900,000 | 6,100,000 | 0.00 | 0.00 | 0.00 | 31,100,000 | 158,000,000 |
| Assets | 4,681,900,000 | 4,864,500,000 | 5,175,000,000 | 6,080,700,000 | 6,445,900,000 | 6,864,900,000 | 5,636,500,000 | 6,102,400,000 | 6,534,700,000 | 7,089,700,000 |
| Liabilities | 3,614,900,000 | 3,248,200,000 | 3,356,300,000 | 4,148,000,000 | 4,444,300,000 | 4,465,700,000 | 3,774,600,000 | 3,805,200,000 | 3,685,500,000 | 3,813,900,000 |
| Stockholders' equity | 735,900,000 | 1,152,500,000 | 1,276,700,000 | 1,352,200,000 | 1,588,000,000 | 1,911,300,000 | 1,310,300,000 | 1,647,500,000 | 2,067,000,000 | 2,438,200,000 |
| Cash and cash equivalents | 40,500,000 | 54,400,000 | 69,200,000 | 60,000,000 | 185,600,000 | 49,400,000 | 21,800,000 | 69,100,000 | 85,400,000 | 72,200,000 |
| Free cash flow |  |  |  |  |  | 170,100,000 | 121,700,000 | 267,700,000 | 360,300,000 | 439,200,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | 6.80% | 6.93% | 6.83% | 7.79% | 7.97% | 10.27% | 6.23% | 7.33% | 8.48% | 9.54% |
| Return on equity | 33.65% | 23.52% | 22.89% | 26.53% | 17.90% | 21.57% | 20.68% | 21.37% | 22.05% | 23.22% |
| Return on assets | 5.29% | 5.57% | 5.65% | 5.90% | 4.41% | 6.00% | 4.81% | 5.77% | 6.97% | 7.99% |
| Liabilities / equity | 4.91 | 2.82 | 2.63 | 3.07 | 2.80 | 2.34 | 2.88 | 2.31 | 1.78 | 1.56 |
| Current ratio | 1.38 | 1.36 | 0.98 | 1.05 | 1.32 | 1.23 | 1.25 | 1.28 | 1.05 | 1.08 |

## As-reported value updates

7 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/EHC/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-07. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000785161.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | 0.45 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 0.87 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | 0.90 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 1,206,900,000 | 85,300,000 | 0.84 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 1,246,800,000 | 87,600,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 1,316,000,000 | 112,500,000 | 1.10 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 1,301,200,000 | 114,100,000 | 1.12 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 1,351,000,000 | 108,200,000 | 1.06 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 1,405,000,000 | 120,900,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 1,455,400,000 | 151,500,000 | 1.48 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 1,457,700,000 | 142,100,000 | 1.39 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 1,477,500,000 | 126,500,000 | 1.24 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 1,544,600,000 | 146,100,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 1,586,600,000 | 194,500,000 | 1.93 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 1,597,400,000 | 153,900,000 | 1.54 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from EHC's latest 10-K: [/company/EHC/business/](/company/EHC/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from EHC's latest 10-K: [/company/EHC/risk-factors/](/company/EHC/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/785161/000078516126000186/ehc-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-08-07
Report date: 2026-06-30

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) relates to Encompass Health Corporation and its subsidiaries and should be read in conjunction with our condensed consolidated financial statements included under Part I, Item 1, Financial Statements (Unaudited), of this report. In addition, the following MD&A should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2025, Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, Part I, Item 1, Business, and Item 1A, Risk Factors, included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed on February 26, 2026 (collectively, the “2025 Form 10‑K”).

This MD&A is designed to provide the reader with information that will assist in understanding our condensed consolidated financial statements, the changes in certain key items in those financial statements from period to period, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our condensed consolidated financial statements. See “Cautionary Statement Regarding Forward-Looking Statements” beginning on page ii of this report, which is incorporated herein by reference for a description of important factors that could cause actual results to differ from expected results. See also Item 1A, Risk Factors, in Part II of this report and Part I of the 2025 Form 10‑K.

Executive Overview

Our Business

We are the nation’s largest owner and operator of inpatient rehabilitation hospitals (“IRFs”) in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment on an inpatient basis. We operate IRFs in 39 states and Puerto Rico, with concentrations in Florida and Texas. As of June 30, 2026, we operated 176 IRFs. For additional information about our business, see Part I, Item 1, Business, and Item 1A, Risk Factors, of the 2025 Form 10‑K.

2026 Overview

During the three and six months ended June 30, 2026, Net operating revenues increased 9.6% and 9.3%, respectively, over the same periods of 2025 due primarily to volume growth and increased pricing. See “Results of Operations” section of this Item for additional volume and pricing information.

In our continued development and expansion efforts during the six months ended June 30, 2026, we:

•began operating our new 49-bed inpatient rehabilitation hospital in Irmo, South Carolina in March;

•began operating our new 50-bed inpatient rehabilitation hospital in Concordville, Pennsylvania in May;

•began operating our new 40-bed inpatient rehabilitation hospital in Loganville, Georgia with our joint venture partner Piedmont in June;

•expanded our capacity by adding 54 new beds to existing hospitals; and

20

•announced or continued the development of the following hospitals:

[[GREPCENT_TABLE]]
[["","Expected open date","Number of New Beds"],["","2026","2027"],["De novo projects(1)"],["Norristown, Pennsylvania","3Q26","50","\u2014"],["Bangor, Maine","4Q26","50","\u2014"],["San Antonio, Texas","4Q26","50","\u2014"],["Avondale, Arizona","4Q26","60","\u2014"],["Wesley Chapel, Florida","","\u2014","50"],["Apollo Beach, Florida","","\u2014","50"],["St. George, Utah","","\u2014","50"],["Fishers, Indiana","","\u2014","50"],["Haslet, Texas","","\u2014","50"],["Flowood, Mississippi","","\u2014","50"],["Cookeville, Tennessee(2)","","\u2014","40"],["Remote and satellite hospitals (included in bed additions)(1)"],["Cleveland, Tennessee","4Q26","40","\u2014"],["Other bed additions","","150 - 200","150 - 200"]]
[[/GREPCENT_TABLE]]

(1) Opening dates are tentative

(2) Expected joint venture

We also continued our shareholder distributions during the six months ended June 30, 2026 through common stock repurchases and paying a quarterly cash dividend. For additional information see the “Liquidity and Capital Resources” section of this Item.

Business Outlook

We remain optimistic regarding the intermediate and long-term prospects of our business. Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide. While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to continue to grow for the foreseeable future. More specifically, the average age of our Medicare patients is approximately 77, and the population group for ages 75 and older is expected to grow at approximately 4% per year through 2030. We believe the demand for the services we provide will continue to increase as the U.S. population ages. We believe these factors align with our strengths in, and focus on, inpatient rehabilitation services.

We are committed to delivering high-quality, cost-effective patient care. As the nation’s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals, we believe we differentiate ourselves from our competitors based on, among other things, the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology. We also believe our competitive strengths discussed in Part I, Item 1, Business, “Competitive Strengths,” of the 2025 Form 10‑K, give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs.

The healthcare industry faces the prospect of ongoing efforts to transform the healthcare system to coordinated care delivery and payment models. The nature, timing and extent of that transformation remains uncertain, as the development and implementation of new care delivery and payment systems will require significant time and resources. Our goal is to position the Company in a prudent manner to be responsive to industry shifts. We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis. We have been disciplined in creating a capital structure that is flexible with no significant debt maturities until 2028. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our ability to adapt to changes in reimbursement, sustain our business model, and grow through new hospitals and bed additions. See also Part I, Item 1, Business, “Strategy and Strategic Priorities” and “Competitive Strengths” of the 2025 Form 10‑K.

21

Key Challenges

Healthcare is a highly regulated industry facing many well-publicized regulatory and reimbursement challenges. The future of many aspects of healthcare regulation generally and Medicare reimbursement specifically remains uncertain. Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care. We believe we have the necessary capabilities—change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities—to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so. For a detailed discussion of the challenges we face, see Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Executive Overview—Key Challenges” of the 2025 Form 10‑K.

As we continue to execute our business plan, the following are some of the key challenges we face.

•Operating in a Highly Regulated Industry. We are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. More specifically, because Medicare comprises a significant portion of our Net operating revenues, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. These rules and regulations have affected, or could in the future affect, our business activities by having an impact on the reimbursement we receive for services provided or the costs of compliance, mandating new documentation standards, requiring additional licensure or certification, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and limiting our ability to enter new markets or add new capacity to existing hospitals. See Part I, Item 1, Business, “Regulation,” and Item 1A, Risk Factors, “Reimbursement Risks” and “Other Regulatory Risks” of the 2025 Form 10‑K for detailed discussions of the most important regulations we face and our programs intended to ensure we comply with those regulations.

•Changes in Medicare Reimbursement and Regulatory Requirements for Operating IRFs. On July 30, 2026, the Centers for Medicare & Medicaid Services (“CMS”) released its notice of final rulemaking for fiscal year 2027 for IRFs (the “2027 Final IRF Rule”) under the inpatient rehabilitation facility prospective payment system. The 2027 Final IRF Rule will implement a net 2.3% market basket increase (market basket update of 3.2% reduced by a productivity adjustment of 0.9%) effective for discharges between October 1, 2026 and September 30, 2027. The 2027 Final IRF Rule also includes changes that impact our hospital-by-hospital base rate for Medicare reimbursement. Such changes include, but are not limited to, revisions to the wage index, updates to outlier payments, and updates to the case-mix group relative weights and average lengths of stay values. The 2027 Final IRF Rule also made updates and clarifications to certain IRF operational requirements. Based on our analysis that utilizes the acuity of our patients annualized over a twelve-month period ended June 30, 2026, our experience with outlier payments over this same time frame, and other factors, we believe the 2027 Final IRF Rule will result in a net increase to our Medicare payment rates of approximately 2.3% effective October 1, 2026.

In August 2023, IRFs located in Alabama began participation in CMS’s review choice demonstration (“RCD”), under which Medicare reimbursement claims are assessed for compliance with applicable coverage and clinical documentation requirements. On June 17, 2024, CMS expanded RCD to include IRFs located in Pennsylvania and billing to a certain Medicare Administrative Contractor (“MAC”). At that time, we did not bill to that MAC, so we were not subject to RCD in Pennsylvania. However, beginning in January 2027, we expect to have two newly opened Pennsylvania IRFs submitting claims under RCD. On March 2, 2026 and May 1, 2026, RCD expanded to Texas and California, respectively. As of June 30, 2026, we have 33 of our IRFs (representing approximately 11.9% of our IRF Medicare claims) subject to RCD. After the initial four states, CMS may expand the demonstration to include additional cohorts of IRFs based on the MAC to which those IRFs submit claims. There are no details of that expansion at this time.

22

Under RCD, each participating IRF has an initial choice between pre-claim or post-payment review of 100% of Medicare claims submitted to demonstrate compliance with applicable requirements during the first six-month review period or cycle. Under the pre-claim review choice, services can begin prior to the submission of the review request and continue while the decision is being made. The pre-claim review request with required documentation must be submitted, reviewed

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/785161/000078516126000081/ehc-20251231.htm
Complete FY 2025 MD&A: /company/EHC/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-02-26
Report date: 2025-12-31

Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the accompanying consolidated financial statements and related notes. This MD&A is designed to provide the reader with information that will assist in understanding our consolidated financial statements, the changes in certain key items in those financial statements from year to year, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our consolidated financial statements. See “Cautionary Statement Regarding Forward-Looking Statements and Summary of Risk Factors” on page ii of this report, which is incorporated herein by reference, for a description of important factors that could cause actual results to differ from expected results. See also Item 1A, Risk Factors.

In addition, management’s discussion and analysis of our results of operations and cash flows for the year ended December 31, 2024 compared to the year ended December 31, 2023 may be found in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on February 28, 2025.

Executive Overview

Our Business

We are the nation’s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment, using advanced technology and intensive therapy, on an inpatient basis for patients recovering from a major injury or illness and seeking to regain functional ability, independence and quality of life. We operate hospitals in 39 states and Puerto Rico, with concentrations in Florida and Texas. As of December 31, 2025, we operated 173 inpatient rehabilitation hospitals. For additional information about our business, see Item 1, Business, and Item 1A, Risk Factors, of this report.

2025 Overview

During 2025, Net operating revenues increased 10.5% over 2024 due primarily to volume growth and increased pricing. See the “Results of Operations” section of this Item for additional volume and pricing information.

We continued our development and expansion efforts in 2025. We:

•began operating our new 40-bed inpatient rehabilitation hospital in Athens, Georgia with our joint venture partner Piedmont in March;

•began operating our new 60-bed inpatient rehabilitation hospital in Fort Myers, Florida with our joint venture partner Lee Healthcare Holdings, LLC in May;

•began operating our new 50-bed inpatient rehabilitation hospital in Daytona Beach, Florida in July;

•began operating our new 40-bed inpatient rehabilitation hospital in Danbury, Connecticut in September;

•began operating our new 50-bed inpatient rehabilitation hospital in St. Petersburg, Florida in October;

•began operating our new 50-bed inpatient rehabilitation hospital in Amarillo, Texas with our joint venture partner BSA Health System in November;

•began operating our new 50-bed inpatient rehabilitation hospital in Lake Worth, Florida in December;

•expanded our capacity by adding 177 new beds to existing hospitals (inclusive of our new 50-bed remote inpatient rehabilitation hospital in Wildwood, Florida (The Villages) which began operating in September); and

50

•announced or continued the development of the following hospitals:

[[GREPCENT_TABLE]]
[["","Expected open date","Number of New Beds"],["","2026","2027"],["De novo projects(1)"],["Irmo, South Carolina","1Q26","49","\u2014"],["Concordville, Pennsylvania","2Q26","50","\u2014"],["Loganville, Georgia(2)","2Q26","40","\u2014"],["Norristown, Pennsylvania","3Q26","50","\u2014"],["San Antonio, Texas","4Q26","50","\u2014"],["Bangor, Maine","4Q26","50","\u2014"],["Avondale, Arizona","4Q26","60","\u2014"],["Wesley Chapel, Florida","","\u2014","50"],["St. George, Utah","","\u2014","50"],["Apollo Beach, Florida","","\u2014","50"],["Haslet, Texas","","\u2014","50"],["Fishers, Indiana","","\u2014","50"],["Remote and satellite hospitals (included in bed additions)(1)"],["Cleveland, Tennessee","4Q26","40","\u2014"],["Other bed additions","","150 - 200","150 - 200"]]
[[/GREPCENT_TABLE]]

(1) Opening dates are tentative

(2) Expected joint venture

We also continued our shareholder distributions in 2025 through common stock repurchases and paying a quarterly cash dividend on our common stock. For additional information on our common stock repurchases and quarterly dividend payments, see the “Liquidity and Capital Resources” section of this Item.

Business Outlook

We remain optimistic regarding the intermediate and long-term prospects of our business. Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide. While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to continue to grow for the foreseeable future. More specifically, the average age of our Medicare patients is approximately 77, and the population group for ages 75 and older is expected to grow at approximately 4% per year through 2030. We believe the demand for the services we provide will continue to increase as the U.S. population ages. We believe these factors align with our strengths in, and focus on, inpatient rehabilitation services.

We are committed to delivering high-quality, cost-effective patient care. As the nation’s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals, we believe we differentiate ourselves from our competitors based on, among other things, the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology. We also believe our competitive strengths discussed in Item 1, Business, “Competitive Strengths,” give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs.

The healthcare industry faces the prospect of ongoing efforts to transform the healthcare system to coordinated care delivery and payment models. The nature, timing and extent of that transformation remains uncertain, as the development and implementation of new care delivery and payment systems will require significant time and resources. Our goal is to position the Company in a prudent manner to be responsive to industry shifts. We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis. We have been disciplined in creating a capital structure that is flexible with no significant debt maturities until 2028. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our ability to adapt to changes in reimbursement, sustain our business model, and grow through de novo hospitals and bed additions. See also Item 1, Business, “Strategy and Strategic Priorities” and “Competitive Strengths.”

51

Key Challenges

Healthcare is a highly regulated industry facing many well-publicized regulatory and reimbursement challenges. The future of many aspects of healthcare regulation generally and Medicare reimbursement specifically remains uncertain. Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care. We believe we have the necessary capabilities—change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities—to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so.

As we continue to execute our business plan, the following are some of the key challenges we face.

•Operating in a Highly Regulated Industry. We are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. More specifically, because Medicare comprises a significant portion of our Net operating revenues, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. These rules and regulations have affected, or could in the future affect, our business activities by having an impact on the reimbursement we receive for services provided or the costs of compliance, mandating new documentation standards, requiring additional licensure or certification, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and limiting our ability to enter new markets or add new capacity to existing hospitals. See Item 1, Business, “Regulation” and Item 1A, Risk Factors, “Reimbursement Risks” and “Other Regulatory Risks” for detailed discussions of the most important regulations we face and our programs intended to ensure we comply with those regulations.

Reimbursement claims made by healthcare providers, including inpatient rehabilitation facilities (“IRFs”), are subject to audit from time to time by governmental payors, such as the Centers for Medicare & Medicaid Services (“CMS”) and state Medicaid programs, their agents, such as the Medicare Administrative Contractors (“MACs”) that act as fiscal intermediaries for all Medicare billings, other auditors contracted by CMS, and private insurance carriers, as well as the United States Department of Health and Human Services Office of Inspector General. These audits as well as the ordinary course claim reviews of our billings result in payment denials, including recoupment of previously paid claims. Healthcare providers can challenge denials through an administrative appeals process that can be extremely lengthy, taking up to several years. For additional details of our claim reviews, see Item 1, Business, “Sources of Revenues,” Item 1A, Risk Factors, “Reimbursement Risks,” and Note 1, Summary of Significant Accounting Policies, “Net Operating Revenues” and “Accounts Receivable,” to the accompanying consolidated financial statements.

•Changes in Medicare Reimbursement and Regulatory Requirements for Operating IRFs. Substantially all of our business consists of inpatient rehabilitation services. From a payor perspective, our reimbursement and regulatory risk is concentrated in the Medicare inpatient rehabilitation rules and regulations. We derive approximately 65% of our Net operating revenues from fee-for-service Medicare and approximately 16% from Medicare Advantage.

As part of its annual rulemaking process for various healthcare provider categories, CMS adopts IRF reimbursement rate changes effective from October through the following September. On August 1, 2025, CMS released its notice of final rulemaking for fiscal year 2026 for IRFs (the “2026 IRF Rule”) under the inpatient rehabilitation facility prospective payment system (the “IRF-PPS”). Based on our analysis that utilizes the acuity of our patients annualized over a twelve-month period ended June 30, 2025, our experience with outlier payments over this same time frame, and other factors, we believe the 2026 IRF Rule will result in a net increase to our Medicare payment rates of approximately 2.9% effective October 1, 2025.

Congress may also adopt legislation that directly affects Medicare reimbursement. These reimbursement changes can result in limitations

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/EHC/mda/fy2025/
All MD&A years: /company/EHC/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/EHC/mda/fy2024/): filed 2025-02-28; accession 0000785161-25-000009 (https://www.sec.gov/Archives/edgar/data/785161/000078516125000009/ehc-20241231.htm)
- [FY 2023 MD&A](/company/EHC/mda/fy2023/): filed 2024-02-28; accession 0000785161-24-000009 (https://www.sec.gov/Archives/edgar/data/785161/000078516124000009/ehc-20231231.htm)
- [FY 2022 MD&A](/company/EHC/mda/fy2022/): filed 2023-02-27; accession 0000785161-23-000012 (https://www.sec.gov/Archives/edgar/data/785161/000078516123000012/ehc-20221231.htm)
- [FY 2021 MD&A](/company/EHC/mda/fy2021/): filed 2022-02-25; accession 0000785161-22-000008 (https://www.sec.gov/Archives/edgar/data/785161/000078516122000008/ehc-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 8060 Services-Hospitals) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [PCE](/indicator/PCE/): Personal Consumption Expenditures
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [UNRATE](/indicator/UNRATE/): Unemployment Rate
- [DSPIC96](/indicator/DSPIC96/): Real Disposable Personal Income

Macro-to-micro threads including this sector: [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/EHC.md · JSON record: /company/EHC.json · verified financials: /company/EHC/financials.json / /company/EHC/financials.csv · machine TOC for the whole site: /llms.txt